Aquestive Therapeutics annual revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aquestive Therapeutics Revenue Growth & History (AQST)
Aquestive Therapeutics reported $44.5M in revenue for fiscal 2025, a decrease of 22.61% from the previous fiscal year.
View full Aquestive Therapeutics company overviewAquestive Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $44.5M | −$13.0M | −22.61% |
| 2024 | 2024-12-31 | $57.6M | $7.0M | +13.80% |
| 2023 | 2023-12-31 | $50.6M | $2.9M | +6.09% |
| 2022 | 2022-12-31 | $47.7M | −$3.2M | −6.20% |
| 2021 | 2021-12-31 | $50.8M | $5.0M | +10.87% |
| 2020 | 2020-12-31 | $45.8M | −$6.8M | −12.85% |
| 2019 | 2019-12-31 | $52.6M | −$14.8M | −21.98% |
| 2018 | 2018-12-31 | $67.4M | $512,000 | +0.77% |
| 2017 | 2017-12-31 | $66.9M | — | — |
Aquestive Therapeutics quarterly revenue
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.8M | $3.8M | +38.15% |
| Q1 2026 | 2026-03-31 | $14.4M | $5.7M | +65.67% |
| Q4 2025 | 2025-12-31 | $13.0M | $1.1M | +9.67% |
| Q3 2025 | 2025-09-30 | $12.8M | −$735,000 | −5.43% |
| Q2 2025 | 2025-06-30 | $10.0M | −$10.1M | −50.23% |
| Q1 2025 | 2025-03-31 | $8.7M | −$3.3M | −27.65% |
| Q4 2024 | 2024-12-31 | $11.9M | −$1.3M | −10.14% |
| Q3 2024 | 2024-09-30 | $13.5M | $540,000 | +4.15% |
| Q2 2024 | 2024-06-30 | $20.1M | $6.9M | +51.79% |
| Q1 2024 | 2024-03-31 | $12.1M | $919,000 | +8.25% |
| Q4 2023 | 2023-12-31 | $13.2M | $2.5M | +23.63% |
| Q3 2023 | 2023-09-30 | $13.0M | $1.5M | +13.43% |
| Q2 2023 | 2023-06-30 | $13.2M | −$24,000 | −0.18% |
| Q1 2023 | 2023-03-31 | $11.1M | −$1.1M | −9.26% |
| Q4 2022 | 2022-12-31 | $10.7M | −$396,000 | −3.57% |
| Q3 2022 | 2022-09-30 | $11.5M | −$1.8M | −13.73% |
| Q2 2022 | 2022-06-30 | $13.3M | −$2.1M | −13.55% |
| Q1 2022 | 2022-03-31 | $12.3M | $1.1M | +10.32% |
| Q4 2021 | 2021-12-31 | $11.1M | $3.9M | +54.96% |
| Q3 2021 | 2021-09-30 | $13.3M | $5.0M | +60.86% |
| Q2 2021 | 2021-06-30 | $15.3M | −$6.3M | −29.20% |
| Q1 2021 | 2021-03-31 | $11.1M | $2.4M | +26.89% |
| Q4 2020 | 2020-12-31 | $7.1M | −$9.3M | −56.46% |
| Q3 2020 | 2020-09-30 | $8.3M | −$4.2M | −33.48% |
| Q2 2020 | 2020-06-30 | $21.7M | $10.5M | +94.76% |
| Q1 2020 | 2020-03-31 | $8.8M | −$3.9M | −30.67% |
| Q4 2019 | 2019-12-31 | $16.4M | −$405,000 | −2.41% |
| Q3 2019 | 2019-09-30 | $12.4M | −$849,000 | −6.40% |
| Q2 2019 | 2019-06-30 | $11.1M | −$2.8M | −20.10% |
| Q1 2019 | 2019-03-31 | $12.6M | −$10.8M | −46.00% |
| Q4 2018 | 2018-12-31 | $16.8M | $4.6M | +37.97% |
| Q3 2018 | 2018-09-30 | $13.3M | −$13.9M | −51.13% |
| Q2 2018 | 2018-06-30 | $13.9M | $2.8M | +25.00% |
| Q1 2018 | 2018-03-31 | $23.4M | $7.0M | +42.44% |
| Q4 2017 | 2017-12-31 | $12.2M | — | — |
| Q3 2017 | 2017-09-30 | $27.1M | — | — |
| Q2 2017 | 2017-06-30 | $11.1M | — | — |
| Q1 2017 | 2017-03-31 | $16.4M | — | — |
Aquestive Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue declined from $45.8M to $44.5M, a compound annual decline of 0.58%. Aquestive Therapeutics's latest reported quarter, Q2 2026, generated $13.8M in revenue, an increase of 38.15% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Aquestive Therapeutics source filings ↗Community posts
Aquestive resubmits Anaphylm application after FDA rejection
Aquestive ($AQST) Therapeutics resubmitted its US new-drug application for Anaphylm, a sublingual film containing dibutepinephrine for severe allergic reactions, including anaphylaxis. The submission responds to the FDA’s earlier complete r ...
